Chandana Javvaji, MD
Hematology & Oncology · Sioux City, IANPI 1821437716
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.0% of the total across 63 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 26 manufacturers, the largest accounting for just 22.7% — the pattern of someone who eats at a lot of different presentations.
Across 63 payments — averaging $20.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$289
- Pfizer$128
- Recordati_rare_diseases_inc.$112
- Boston Scientific$108
- AstraZeneca$82
- Gilead$59
- plus $496 from 20 others
What the payments were for
- Food & beverage$1,23697%
- Education$383%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 16 | $289 |
| Pfizer | 7 | $128 |
| Recordati_rare_diseases_inc. | 1 | $112 |
| Boston Scientific | 1 | $108 |
| AstraZeneca | 4 | $82 |
| Gilead | 4 | $59 |
| Bristol Myers Squibb | 3 | $49 |
| Octapharma USA, Inc. | 2 | $46 |
| Merck | 3 | $43 |
| Johnson & Johnson | 2 | $35 |
| AbbVie | 2 | $33 |
| Sobi, Inc | 2 | $28 |
| Genentech USA, Inc. | 1 | $28 |
| Amgen | 2 | $26 |
| CTI Biopharma Corp. | 2 | $25 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $21 |
| Jazz Pharmaceuticals Inc. | 1 | $18 |
| Janssen Scientific Affairs, LLC | 1 | $18 |
| Taiho Oncology, Inc. | 1 | $18 |
| Springworks Therapeutics, Inc. | 1 | $17 |
| Ipsen Biopharmaceuticals, Inc | 1 | $16 |
| Sumitomo Pharma America, Inc. | 1 | $16 |
| Eisai Inc. | 1 | $15 |
| Sun Pharmaceutical Industries Inc. | 1 | $15 |
| Aurobindo Pharma USA, Inc. | 1 | $14 |
| Novartis | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ENJAYMO$112
- THERASPHERE$108
How this compares
$1,273 in reported general payments places this provider in the 55th percentile of 75 hematology & oncology providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ImbruvicaIbrutinib | 58 | $912,065 |
| CalquenceAcalabrutinib Maleate | 42 | $631,260 |
| IbrancePalbociclib | 20 | $324,757 |
| XtandiEnzalutamide | 22 | $292,331 |
| BrukinsaZanubrutinib | 12 | $180,608 |
| RevlimidLenalidomide | 14 | $172,316 |
| Abiraterone Acetate | 11 | $36,300 |
| EliquisApixaban | 51 | $34,395 |
| Anastrozole | 382 | $4,177 |
| Exemestane | 40 | $2,952 |
| Letrozole | 66 | $962 |
| Hydroxyurea | 42 | $815 |
| Acyclovir | 69 | $750 |
| Fluconazole | 13 | $734 |
| Dexamethasone | 62 | $587 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $21 | $912,06558 claims |
| AstraZenecaCalquence | $82 | $631,26042 claims |
| PfizerIbrance, Eliquis | $128 | $359,15271 claims |
| Bristol Myers SquibbRevlimid | $49 | $172,31614 claims |
| Janssen Scientific Affairs, LLCAbiraterone Acetate | $18 | $36,30011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 75 hematology & oncology providers in Iowa.
Other hematology & oncology in Sioux City
- Donald WenderSioux City$22K
- Nibash BudhathokiSioux City$5K
- Radha RaoSioux City$2K
- Sakeer HussainCouncil Bluffs$74K
- Usha PerepuIowa City$70K
- Umang SwamiIowa City$54K
- Umar FarooqIowa City$30K
- Brian LinkIowa City$26K
- Mark KarwalIowa City$25K
- Kartik AnandWest Des Moines$24K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.